A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 14830 participants.
Also called NCT05643573
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 14,830 participants
- Sponsor
- Registry
-
NCT05643573 -
2022-000758-28
-
- Other papers using this trial's data
- Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial
- Asundexian versus Apixaban in Patients with Atrial Fibrillation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Romania, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05643573. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-05 (actual); primary completion 2024-01-31 (actual). Results posted on 2024-12-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
- Acronym
- OCEANIC-AF
- Condition
- Prevention of Stroke or Systemic Embolism
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Asundexian (BAY2433334)
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Asundexian matching placebo
- Intervention (Drug)
- Apixaban matching placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct05643573- Content hash
a63ef33f041cb93a049ff79e4e6e398ace760bb6e45fd0970071935288f24954